<DOC>
	<DOCNO>NCT00856206</DOCNO>
	<brief_summary>The purpose clinical research study determine safety effectiveness experimental drug call rilonacept subject gout urate-lowering therapy . Subjects participate study approximately 20 week . Rilonacept study use prevent gout flare subject urate-lowering therapy .</brief_summary>
	<brief_title>Review Safety Using Rilonacept Preventing Gout Exacerbations ( RE-SURGE )</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<criteria>Male female 18 80 year age Previously meet preliminary criterion ARA classification acute gout arthritis primary gout Subjects history gout , initiate currently urate lower therapy risk gout flare Acute gout flare within 2 week prior Screening Visit screen visit Persistent chronic active infection History allergic reaction allopurinol History presence cancer within 5 year Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Metabolism , Inborn Errors</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Metabolic Disease</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatic Diseases</keyword>
	<keyword>Metabolic disorder</keyword>
	<keyword>Purine Pyrimidine Metabolism , Inborn Errors</keyword>
	<keyword>Gout</keyword>
	<keyword>Intercritical Gout</keyword>
</DOC>